J. Ball, M. J. Carrington, and J. J. Mcmurray, Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century, Int J Cardiol, vol.167, pp.1807-1831, 2013.

A. J. Camm, G. Y. Lip, D. Caterina, and R. , 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillationdeveloped with the special contribution of the European Heart Rhythm Association, Europace, vol.14, pp.1385-413, 2012.

C. T. January, L. S. Wann, and J. S. Alpert, AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, vol.64, pp.1-76, 2014.

C. Jones, V. Pollit, and D. Fitzmaurice, The management of atrial fibrillation: summary of updated NICE guidance, BMJ, vol.348, p.3655, 2014.

A. Verma, J. A. Cairns, and L. B. Mitchell, focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation, Can J Cardiol, vol.30, pp.1114-1144, 2014.

J. J. You, D. E. Singer, and P. A. Howard, Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, vol.141, pp.531-75, 2012.

R. G. Hart, L. A. Pearce, and M. I. Aguilar, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, vol.146, pp.857-67, 2007.

D. Caterina, R. Husted, S. Wallentin, and L. , General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis: Task Force on Anticoagulants in Heart Disease, Thromb Haemost, vol.109, pp.569-79, 2013.

S. D. Fihn, C. M. Callahan, and D. C. Martin, The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics, Ann Intern Med, vol.124, pp.970-979, 1996.

S. J. Connolly, M. D. Ezekowitz, and S. Yusuf, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, pp.1139-51, 2009.

M. R. Patel, K. W. Mahaffey, and J. Garg, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, vol.365, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

C. B. Granger, J. H. Alexander, and J. J. Mcmurray, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.365, pp.981-92, 2011.

C. T. Ruff, R. P. Giugliano, and E. Braunwald, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, vol.383, pp.955-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935589

T. S. Potpara and G. Y. Lip, Novel oral anticoagulants in non-valvular atrial fibrillation, Best Pract Res Clin Haematol, vol.26, pp.115-144, 2013.

A. M. Shields and G. Y. Lip, Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation, J Intern Med, vol.278, pp.1-18, 2015.

H. Autorité-de-santé, Fibrillation auriculaire non valvulaire: Quelle place pour les anticoagulants oraux non antivitamine K:apixaban (Eliquis®), dabigatran (Pradaxa®) et rivaroxaban (Xarelto®, 2013.

C. Ferdynus and L. Huiart, Technical improvement of cohort constitution in administrative health databases: Providing a tool for integration and standardization of data applicable in the French National

, Rev Epidemiol Sante Publique, vol.64, pp.263-272, 2016.

J. Bezin, M. Duong, and R. Lassalle, The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology, Pharmacoepidemiol Drug Saf, vol.26, pp.954-62, 2017.

K. Martin-latry and B. Bégaud, Pharmacoepidemiological research using French reimbursement databases: yes we can!, Pharmacoepidemiol Drug Saf, vol.19, pp.256-65, 2010.

A. Palmaro, G. Moulis, and F. Despas, Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies, Fundam Clin Pharmacol, vol.30, pp.616-640, 2016.

R. Pisters, D. A. Lane, and R. Nieuwlaat, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, vol.138, pp.1093-100, 2010.

G. Y. Lip, R. Nieuwlaat, and R. Pisters, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation, Chest, vol.137, pp.263-72, 2010.

K. Kirley, D. M. Qato, and R. Kornfield, National trends in oral anticoagulant use in the United States, Circ Cardiovasc Qual Outcomes, vol.5, pp.615-636, 2007.

G. D. Barnes, E. Lucas, and G. C. Alexander, National trends in ambulatory oral anticoagulant use, Am J Med, vol.128, pp.1300-1305, 2015.

S. Y. Loo, S. Dell'aniello, and L. Huiart, Trends in the prescription of novel oral anticoagulants in UK primary care, Br J Clin Pharmacol, vol.83, pp.2096-106, 2017.

B. A. Steinberg, D. N. Holmes, and J. P. Piccini, Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation, J Am Heart Assoc, vol.2, p.535, 2013.

R. Sørensen, G. Gislason, and C. Torp-pedersen, Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study, BMJ Open, vol.3, p.2758, 2013.

G. Y. Lip, C. Laroche, and G. A. Dan, Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey, Am J Med, vol.127, pp.519-548, 2014.

N. Mochalina, A. Jöud, and M. Carlsson, Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: a population-based cohort study, Thromb Res, vol.140, pp.94-103, 2016.

N. R. Desai, A. A. Krumme, and S. Schneeweiss, Patterns of initiation of oral anticoagulants in patients with atrial fibrillation-quality and cost implications, Am J Med, vol.127, pp.1075-82, 2014.

T. B. Larsen, T. Potpara, and N. Dagres, Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey, Europace, vol.17, pp.819-843, 2015.

F. J. Garjón, A. Azparren, and I. Vergara, Adoption of new drugs by physicians: a survival analysis, BMC Health Serv Res, vol.12, p.56, 2012.

W. Opstelten, M. Van-den-donk, and T. Kuijpers, New oral anticoagulants for nonvalvular atrial fibrillation in the elderly: limited applicability in primary care, Eur J Gen Pract, vol.21, pp.1-5, 2015.

G. Y. Lip and D. A. Lane, Stroke prevention in atrial fibrillation: a systematic review, JAMA, vol.313, pp.1950-62, 2015.

T. Wisløff, G. Hagen, and M. Klemp, Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation, Pharmacoeconomics, vol.32, pp.601-613, 2014.

S. Schneeweiss, J. J. Gagne, and R. J. Glynn, Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development, Clin Pharmacol Ther, vol.90, pp.777-90, 2011.

, Xarelto (rivaroxaban): mise en garde sur les facteurs de risques hémorragiques -Lettre aux professionnels de santé, Agence Nationale de Sécurité du Médicament et des produits de santé. Nouveaux anticoagulants oraux Eliquis (apixaban), Pradaxa (dabigatran), 2013.

H. Autorité-de-santé, Les anticoagulants oraux antivitamine K restent la référence dans la fibrillation auriculaire non valvulaireCommuniqué de presse, 2013.

H. Autorité-de-santé, Point sur l'utilisation des nouveaux anticoagulants oraux -Communiqué de Presse, 2013.

P. Tuppin, J. Rudant, and P. Constantinou, Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France, Rev Epidemiol Sante Publique, vol.65, issue.4, pp.149-167, 2017.